ADBiotech Co., Ltd.
Financials
Valuation Metrics
ADBiotech Co., Ltd.'s Market Cap is ₩588B. At end of 2025 it was ₩547B. Ranked #1628 of 2,436 in KR market (top 67%), #962 of 1,649 on KOSDAQ (top 58%), #181 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 58.75B KRW | KR#1,628/2,436 Sec#181/234 |
| Revenue | 12.51B KRW | KR#2,256/2,436 Sec#171/234 |
| Net Income | -8.13B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 42.56B KRW | KR#2,249/2,436 Sec#206/234 |
| Net Assets | 13.57B KRW | KR#2,338/2,436 Sec#221/234 |
| Employees | 57 | KR#1,967/2,436 Sec#173/234 |
| Value | ||
| P/B | 4.33x | KR#2,219/2,436 Sec#184/234 |
| P/S | 4.70x | KR#2,133/2,436 Sec#138/234 |
| FCF Yield | -2.89% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -59.91% | KR#2,290/2,436 Sec#205/234 |
| ROA | -19.10% | KR#2,223/2,436 Sec#174/234 |
| Op. Margin | -34.86% | KR#2,195/2,436 Sec#156/234 |
| Revenue Growth | -11.13% | KR#1,907/2,436 Sec#174/234 |
| Financial Health | ||
| Debt Ratio | 313.64% | KR#2,159/2,436 Sec#222/234 |
| Total Debt | 24.45B KRW | KR#1,285/2,436 Sec#106/234 |
| FCF | -1.70B KRW | KR#1,322/2,436 Sec#103/234 |
| Cash | 4.94B KRW | KR#1,994/2,436 Sec#182/234 |
| Current Ratio | 0.48x | KR#2,267/2,436 Sec#218/234 |
| Performance | ||
| 1Y Return | -44.46% | KR#1,954/2,436 Sec#174/234 |
| 1M Return | 8.46% | KR#381/2,436 Sec#28/234 |
| From 52W High | -50.29% | KR#1,217/2,436 Sec#104/234 |
| 1Y MDD | -70.56% | KR#1,977/2,436 Sec#174/234 |
| Trading | ||
| Volume | 157,540 shares | KR#1,443/2,436 Sec#141/234 |
| Foreign Own. | 1.71% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -579 KRW | KR—/2,436 Sec—/234 |
| BPS | 781 KRW | KR#2,333/2,436 Sec#213/234 |
Company Info
Addbio Tech, established in 2000 and headquartered in Chuncheon-si, Gangwon-do, is an eco-friendly biotechnology company researching immune antibodies to develop vaccines and antibiotic alternatives. The company possesses key pipelines, including IgY immune egg yolk antibodies, VHH antibodies, microbial agents, and scFv antibodies, ensuring high stability through both egg-derived and camelid-derived antibody technologies. Addbio Tech is developing products to meet the growing demand for livestock infectious disease solutions and vaccine alternatives, actively expanding its global market presence, particularly through China and Southeast Asia.